Gastroparesis Drug Market Report 2034: Epidemiology, Latest FDA Approvals | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.

DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover which therapies are expected to grab the Gastroparesis Market Share @ Gastroparesis Market Outlook- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastroparesis Market Report
• The total Gastroparesis prevalent cases in the 7MM were around ~7,200,000 cases in 2023 out of which the highest Gastroparesis prevalent cases were seen in the United States.
• Gastroparesis as a disease predominantly affects women, with ~68.5% of the diagnosed patients being females, while only ~31.5% of the diagnosed patients are males.
• As per the DelveInsight estimates, United States has the largest share of diagnosed Gastroparesis cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2020-2034.
• The leading Gastroparesis Companies working in the market include Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Promising Gastroparesis Pipeline Therapies in the various stages of development include Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.
• April 2024:- CinDome Pharma Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis. The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
• March 2024:- Vanda Pharmaceuticals- VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis. To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiological Insights- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Overview
Gastroparesis is a medical condition that affects the normal movement of muscles in the stomach, leading to delayed emptying of food into the small intestine. This delay in digestion can cause various symptoms such as nausea, vomiting, bloating, abdominal pain, feeling full quickly, and changes in blood sugar levels. It's often caused by damage to the vagus nerve, which controls the muscles of the stomach, or by damage to the muscles themselves. It can be associated with conditions like diabetes, neurological diseases, or certain medications. Treatment usually involves dietary changes, medication to stimulate stomach emptying, and in severe cases, surgery may be necessary.

Gastroparesis Epidemiology Segmentation in the 7MM
• Gastroparesis Prevalent cases
• Gastroparesis Gender-specific Diagnosed cases
• Gastroparesis Cause-specific Diagnosed cases
• Gastroparesis Treated cases
• Gastroparesis Age-specific Diagnosed Cases
• Gastroparesis Diagnosed Prevalent cases

To know more about Gastroparesis treatment guidelines, visit @ Gastroparesis Treatment Market Landscape- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Market Insights
Management of Gastroparesis involves correcting fluid, electrolyte, and nutritional deficiencies, identifying and treating the cause of delayed gastric emptying (for example, diabetes mellitus), and suppressing or eliminating symptoms. Therapeutic strategies rely on dietary modification, medications that stimulate gastric motor activity, antiemetic drug therapy, and nonpharmacological measures such as endoscopic or surgical intervention or gastric electrical stimulation.

Gastroparesis Treatment Landscape
The Gastroparesis treatment is based on the severity of the symptoms of the disease. If diabetes is associated with Gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

Learn more about the FDA-approved drugs for Gastroparesis @ Drugs for Gastroparesis Treatment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroparesis Marketed Therapies
• GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma
Metoclopramide hydrochloride, the active ingredient in GIMOTI, is a dopamine-2 receptor antagonist. GIMOTI, a dopamine antagonist/mixed 5-HT3 antagonist/5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis.

Gastroparesis Emerging Therapies
• VLY-686 (tradipitant): Vanda Pharmaceuticals
• PCS12852: Processa Pharmaceuticals

Major Gastroparesis Companies
Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.

Scope of the Gastroparesis Market Report
• Coverage- 7MM
• Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, Cin Dome Pharma, and others.
• Gastroparesis Therapies- Velusetrag, tadalafil, PCS12852, Naronapride, CIN-102 Dose 1, Metoclopramide Nasal Spray, and others.
• Gastroparesis Market Dynamics: Gastroparesis Market Drivers and Barriers
• Gastroparesis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Gastroparesis Drugs in development @ Gastroparesis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Gastroparesis
4. Gastroparesis Market Overview at a Glance
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Gastroparesis: Six Major Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.